Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World November 4, 2015 Phillip Broadwith	Shire to buy cardiovascular specialist Dyax The deal gives Shire access to Dyax's portfolio of approved and developmental drugs for treating hereditary angioedema.
The Motley Fool May 10, 2011 Brian Orelli	Uncontrolled Crying Over AVANIR's Prescription Data? It's been a slow start, but don't write off this company's pseudobulbar drug just yet.
The Motley Fool December 3, 2009 Brian Orelli	I Love This Industry With double-digit gains, how could you not love the biotech industry?
The Motley Fool July 16, 2008 Brian Lawler	A Big Move From ViroPharma ViroPharma picks up an asset that's more than half its size.
Chemistry World November 11, 2013 Phillip Broadwith	Shire will cut UK R&D to focus on rare diseases Shire Pharmaceuticals has begun an employee consultation process as it seeks to discontinue a significant proportion of research and development activities at its historic UK base in Basingstoke.
Pharmaceutical Executive September 1, 2008 Jeffrey S. Aronin	The Orphan Opportunity The Orphan Drug Act was passed 25 years ago. But the challenge of actually getting rare disease drugs and therapies to patients still remains
The Motley Fool May 12, 2011 Brian Orelli	ViroPharma Gives It a Shot Testing a subcutaneous form of Cinryze.
The Motley Fool May 26, 2009 Brian Orelli	Will the FDA Approve These Drugs? Plenty of Prescription Drug User Fee Act dates are right around the corner. Read on to see which pharma companies may be affected.
Chemistry World September 11, 2012 Maria Burke	Orphan drugs set for 'tremendous growth' A new report by Thomson Reuters offers clear confirmation that developing drugs for rare, or orphan, diseases is economically attractive, despite the smaller patient pool.
The Motley Fool December 29, 2011 Brian Orelli	Too Early for a New Biotech Orphan? Alexion Pharmaceuticals is profitable with a drug on the market. The next logical step in the progression of a biotech is to buy another company to stock the pipeline.
The Motley Fool November 24, 2010 Sean Williams	ViroPharma: Bargain or Value Trap? Generic competition and production issues are major red flags.
The Motley Fool February 28, 2011 Brian Orelli	Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on.
The Motley Fool February 9, 2009 Brian Orelli	ViroPharma Cut in Half ViroPharma's phase 3 drug, maribavir, failed to show an effect in reducing cytomegalovirus (CMV) disease in stem cell transplant patients, and the stock gets axed in half.
The Motley Fool August 5, 2009 Brian Orelli	The Cash Cow Is Out of Milk ViroPharma has milked its antibiotic Vancocin, which it bought from Eli Lilly in 2004, pretty well, but it looks like the cash cow is finally running dry.
The Motley Fool July 23, 2009 Brian Orelli	This Too Shall Pass ... Like a Kidney Stone Demand outstrips supply? Boo-hoo. Lowered guidance because a company can't make enough to keep up with demand. Example: Genzyme
Chemistry World January 26, 2015 Phillip Broadwith	Shire deepens rare disease focus with NPS buyout UK specialty pharmaceutical firm Shire has agreed to buy US biotech NPS Pharmaceuticals for $5.2 billion.
The Motley Fool May 30, 2006 Rich Duprey	NICE Not Playing Nice With Alzheimer's The British health authority proposes limiting availability of Alzheimer's treatments because of cost. What will this mean to drug-makers and their shareholders?
The Motley Fool November 27, 2009 Brian Orelli	Biotech Bargains for Your Portfolio Everyone is looking for bargains this time of year. That includes pharmaceutical giants looking to pick up some biotechs on the discount rack, and investors trying to get there first.
Managed Care February 2005 Mark Zitter	Managing Drugs for Rare Genetic Diseases: Trends and Insights Evaluates recent trends and challenges in health system management of exceedingly rare genetic diseases, from the perspective of the manufacturer, managed care organization, physician, and actuary.
Managed Care September 2004 Thomas Morrow	Orphan Drug Act Treatments Deserve Full Insurance Coverage An important federal law encourages development of drugs for populations so small that the market would otherwise ignore them. Should they not then be covered?
The Motley Fool March 27, 2009 Brian Orelli	Dyax: A Cinderella Story Ends in a Fall FDA asks Dyax for more information.
The Motley Fool February 26, 2007 Brian Lawler	Shire's Busy Week Shire Pharmaceuticals announces year-end results, new regulatory approval, and another acquisition.
The Motley Fool August 29, 2011 Brian Orelli	Drug Approved for Few Patients -- but That's OK The age of personalized medicine is upon us. Earlier this month, the FDA approved Roche's melanoma drug Zelboraf for patients with a specific mutation in BRAF. And on Friday, the agency approved Pfizer's Xalkori for lung cancer patients that are ALK-positive.
The Motley Fool October 22, 2010 Brian Orelli	No Swelling Sales Here ViroPharma saw its stellar launch of hereditary angioedema treatment Cinryze come to a standstill until it could scale up manufacturing further.
BusinessWeek March 14, 2005 Arnst & Barrett	Another Ailing Miracle Drug Biogen's troubles with Tysabri are a setback for immune-system treatments
The Motley Fool March 3, 2011 Ryan McBride	With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players.
The Motley Fool May 21, 2007 Brian Lawler	DUSA's Orphan Isn't Unique The pharmaceutical gets "orphan drug" status for its lead compound. Investors, take note.
The Motley Fool February 14, 2008 Brian Orelli	Drug Developer Displays Its Goods Dyax strikes a licensing deal with Sanofi-Aventis, sending shares soaring. Investors, take note.
The Motley Fool May 29, 2009 Brian Orelli	The Clouds Are Parting The Food and Drug Administration has scheduled an advisory committee meeting for Aug. 4 to get input on whether the agency should approve generic versions of ViroPharma's antibiotic, Vancocin.
Pharmaceutical Executive April 1, 2012 Feam & Lagus	Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help.
The Motley Fool June 30, 2008 Brian Orelli	Johnson & Johnson Grows Up a Little Its Concerta for attention-deficit disorder is approved for use in adults.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
Chemistry World October 8, 2010 Sarah Houlton	U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness.
The Motley Fool March 13, 2009 Brian Orelli	Will These Drugs Get Past the FDA? Let's take a look at which pharma companies are hoping to score with the FDA this month.
The Motley Fool February 26, 2007 Rich Duprey	Foolish Forecast: Getting Indigestion With ViroPharma The small-cap pharmaceutical will report its fourth-quarter 2006 financial results shortly. Investors, here is what you can expect to see.
BusinessWeek January 30, 2006 Catherine Arnst	Going Broke To Stay Alive Rising prices for cancer treatments are making patients - and doctors - balk.
The Motley Fool October 30, 2006 Brian Lawler	Building a Future Shire ADHD drugs are big for Shire now, but the long term isn't as clear. Investors, take note.
The Motley Fool June 21, 2005 Charly Travers	A Biotech Bargain Paying $1.6 billion for a robust pipeline and promising future may be a steal. Purchasing Transkaryotic's drug portfolio should pay off very soon for the specialty pharmaceutical Shire.
The Motley Fool October 9, 2007 Brian Lawler	Shire Slims Down, Slightly The U.K.-based pharmaceutical sells off some of its marketed drugs in order to focus more on its key ADHD franchises.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
The Motley Fool April 4, 2011 Brian Orelli	Anti-Infective, Very Effective The FDA seems to like Optimer's new antibiotic.
Chemistry World May 31, 2013 Phillip Broadwith	Two new 'personalized' cancer drugs approved Two new drugs for the most deadly kind of skin cancer have been approved by the US Food and Drug Administration. The drugs are only effective in patients whose tumors express specific genetic mutations, which can be identified using a device approved alongside the drugs.
The Motley Fool November 21, 2007 Brian Lawler	Black Friday Bargain Stock: ViroPharma Is ViroPharma a good value right now? With competition worries out of the way, and a strong and growing cash flow, it won't take much success for value investors to be rewarded.
The Motley Fool July 9, 2008 Brian Lawler	ViroPharma Makes Its Case Rather than taking the more traditional route, ViroPharma has taken steps to try to make it significantly harder than normal for a generic-drug maker to attack its lead drug, Vancocin.
The Motley Fool March 30, 2009 Brian Orelli	Change the Game? Change the Rules! There are ways for investors to get around Obama's plan to lower health care costs. Investing in drug companies in this time of "change" doesn't have to be scary. You've just got to find rule breaker-type drugmakers, because playing by the rules isn't going to cut it anymore.
BusinessWeek September 5, 2005 Capell & Arndt	Drugs Get Smart Future medicines will more effectively target what ails you by tailoring treatment to your specific genetic profile. Personalized medicine will also help prevent another Vioxx.
The Motley Fool February 24, 2011 Brian Orelli	Profit From Personalized Medicine Pfizer's drug works well, but consider these companies instead.
Managed Care July 2003 John Carroll	CMS Move Threatens To Put Orphan Drugs Out in Cold Have drug companies lost the incentive to develop products for small populations? What's managed care's stake?
The Motley Fool November 3, 2006 Brian Lawler	Nothing's Wrong With ViroPharma Despite potential generic competition on the horizon, the company is going strong. Vancocin's fate will determine how well shares of ViroPharma perform in the near future.
The Motley Fool March 31, 2011 Brian Orelli	Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones?